EWM
LCTX icon

EPG Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

EPG Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14
Closed – – 490
2020
Q1 		$0 Buy
+14
New +$14 ﹤0.01% 827

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EPG Wealth Management's LCTX Position: Q2 2020 in Review

EPG Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2020, closing a stake of 14 shares.

EPG Wealth Management first reported a position in LCTX in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 94 funds tracked by Wall St. Rank hold LCTX as of Q2 2020.

  • EPG Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q2 2020 after selling out during the quarter.
  • EPG Wealth Management sold 14 Lineage Cell Therapeutics shares in Q2 2020.
  • EPG Wealth Management first reported a position in Lineage Cell Therapeutics in Q1 2020 and held it in 1 quarter.
  • EPG Wealth Management's Lineage Cell Therapeutics position peaked at $0 in Q1 2020.
  • 94 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2020.

Based on EPG Wealth Management's 13F filing for Q2 2020, filed 6 Aug 2020.